Jessica Palmer, Stemina’s Associate Director of Toxicology, will present at the Teratology Society’s 57^th Annual Meeting, held June 24-28, 2017 in Denver. Anyone interested in developmental toxicity assays is encouraged to attend.

Prediction of Developmental Toxicity Potential by In Vivo Exposures with a Biomarker-Based Human Pluripotent Stem Cell Assay

This presentation is part of Platform Session 2: Mechanistic and Clinical Teratology
Monday, June 26 | 9:15 AM
Colorado Ballroom B

About the presentation

Previous approaches for evaluating the accuracy of alternative test methods have been based on the classification of a chemical as either a positive or a negative, with no other distinction. This method does not mimic the in vivo situation, where a chemical is positive or negative in the context of dose level. 

The Developmental and Reproductive Toxicology Technical Committee of the ILSI Health and Environmental Sciences Institute has published a list of positive and negative developmental exposures, with exposure defined by toxicokinetic data, specifically maternal plasma Cmax and embryo concentrations (Daston et al., 2014). We tested this chemical/exposure set with a previously developed, predictive, in vitro human pluripotent stem cell-based targeted biomarker assay (devTOX^{qP TM}). 

The devTOX^{qP TM} assay was designed around the premise that manifestation of developmental toxicity is dependent to a large degree on chemical dose.